Zepbound, obstructive sleep apnea and FDA

Patients taking a compounded alternative to Eli Lilly's weight loss drug Zepbound will need to transition to the name-brand ...
The decision will largely prevent compounding pharmacies from making and selling compounded versions of the drug in the next two to three months.
Eli Lilly’s Zepbound drug holds potential to dominate the global obesity market due to its superior efficacy and strategic ...